PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery systems
- None.
- None.
The partnership between PassPort Technologies and Arcturus Therapeutics marks a significant convergence of biotechnology and drug delivery systems. This collaboration is poised to enhance the delivery mechanism of mRNA vaccines and therapeutics, potentially increasing efficacy and patient compliance. The use of Arcturus's LUNAR® platform could signify a leap in the stability and efficiency of mRNA formulations. The transdermal approach by PassPort may offer a non-invasive alternative to traditional injections, which could lead to broader acceptance and ease of administration.
From an investment perspective, this collaboration could lead to the development of novel therapeutics with competitive advantages in the market. If successful, the integration of these technologies might result in a new class of accessible mRNA-based treatments, potentially impacting ARCT's market share and growth trajectory. Moreover, the diversification into transdermal delivery could open additional markets and revenue streams for both companies involved.
The strategic alliance between PPTI and ARCT is likely to be closely monitored by the pharmaceutical industry, as it represents a novel approach in drug delivery. The success of this collaboration could disrupt the vaccine and therapeutic markets, especially if the transdermal delivery system demonstrates comparable or superior efficacy to current delivery methods. Market acceptance of such innovative technology could shift consumer and healthcare provider preferences, potentially leading to a reevaluation of existing market strategies by competitors.
Investors should consider the potential long-term implications for the pharmaceutical sector. The research outcome could affect not only the stock performance of the companies involved but also set a precedent for future biotech partnerships. The potential for patentable technologies arising from this collaboration could also lead to lucrative licensing deals or partnerships, further affecting the financial landscape of the biotech industry.
The clinical implications of a successful transdermal mRNA delivery system are profound. The non-invasive nature of this technology could significantly improve patient adherence, particularly in populations with needle phobia or limited access to healthcare facilities. Additionally, if the transdermal system can maintain the integrity and potency of mRNA molecules, it could result in a new paradigm for vaccine and therapeutic administration, potentially reducing side effects and improving therapeutic outcomes.
Given the complexity of mRNA stability and the skin's barrier function, the clinical trials resulting from this research will be critical in determining the viability of the transdermal approach. The data generated will be essential for regulatory approval processes and could set new standards for drug delivery in the future. The success of these trials could have a substantial impact on the future research directions and funding in the field of transdermal drug delivery.
Arcturus's mRNA medicines and vaccines and lipid-mediated drug delivery systems in combination with PassPort's innovative transdermal drug delivery system.
SAN DIEGO, Jan. 5, 2024 /PRNewswire/ -- PassPort Technologies, Inc. (PPTI), led by President and CEO Tomoyuki Fujisawa in
The research collaboration will leverage ARCT's expertise in mRNA design and proprietary LUNAR® platform technologies, alongside PPTI's groundbreaking PassPort® transdermal drug delivery technology. PPTI will utilize its unique platform technology and extensive knowledge in transdermal biologics and oligonucleotides delivery. ARCT will supply select mRNA and LUNAR® formulations, which PPTI will subsequently adapt to the PassPort® system.
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed Kostaive™, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in
About PassPort Technologies, Inc.
As a cutting-edge biotechnology entity, PPTI is committed to the swift development and patient delivery of exceptional pharmaceuticals through the PassPort system. The company aims to constantly develop technologies that serve not only the pharmaceutical industry but also broader life sciences sectors. PPTI's mission is to advance global health outcomes. Further details can be found at https://passport-tech.com.
About PassPort® Technology
The PassPort® System integrates microporation technology to painlessly form micropores in the skin seamlessly and a patch formulation technology that regulates drug delivery through these micropores. This innovative system now enables transdermal delivery of biologics and oligonucleotides, which were previously limited to injections and infusions.
■For inquiries regarding this matter, please contact:
E-mail: info@passport-tech.com
URL: https://passport-tech.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/passport-technologies-commences-collaborative-research-with-arcturus-therapeutics-to-evaluate-transdermal-mrna-delivery-systems-302027399.html
SOURCE PassPort Technologies, Inc.
FAQ
What is the collaborative research endeavor between PassPort Technologies, Inc. (PPTI) and Arcturus Therapeutics (ARCT)?
Who is the President and CEO of PassPort Technologies, Inc. (PPTI)?
What is the focus of the research collaboration between PassPort Technologies, Inc. (PPTI) and Arcturus Therapeutics (ARCT)?
What technologies will be leveraged in the research collaboration?
What will PassPort Technologies, Inc. (PPTI) supply for the collaborative research?
